氟哌噻吨美利曲辛治疗感觉敏感性膀胱过度活动症的疗效研究

俞江; 王博; 吕婷婷; 顾寅珺; 方伟林; 蒋晨; 吕坚伟

doi:10.13201/j.issn.1001-1420.2020.12.009

氟哌噻吨美利曲辛治疗感觉敏感性膀胱过度活动症的疗效研究

- 1. 上海交通大学医学院附属仁济医院泌尿外科(上海, 200127);
- 2. 上海交通大学医学院附属苏州九龙医院泌尿外科
基金项目:
上海市综合医院中西医结合专项建设项目(No:ZHYY-ZXYJHZX-201601)

上海市卫生和计划生育委员会科研课题项目(No:201840114)

详细信息

通讯作者: 吕坚伟,E-mail:jvwass@126.com

中图分类号: R694

收稿日期: 2020-04-18

Study on the efficacy of flupentixol melitracen in the treatment of hypersensitive overactive bladder syndrome

- 1. Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China;
- 2. Department of Urology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine

More Information

Corresponding author: LV Jianwei, E-mail: jvwass@126.com

Received Date: 18 April 2020

摘要

摘要: 目的:探讨氟哌噻吨美利曲辛治疗感觉敏性膀胱过度活动症(OAB)的临床疗效。方法:2019年7月~2019年12月门诊就诊的OAB患者中,选取临床以时刻尿意感为主要症状、尿动力检查膀胱初始尿意容量＜150 mL且无明显逼尿肌过度活动的女性OAB患者72例,随机分为氟哌噻吨美利曲辛试验组36例和托特罗定对照组36例,试验组每天口服氟哌噻吨美利曲辛1片(含氟哌噻吨0.5 mg和美利曲辛10 mg),对照组每天口服托特罗定缓释片4 mg,两组治疗周期均为12周,每组患者治疗前后分别评估24 h排尿日记、OABSS评分、OAB-V8评分、生活质量QOL评分以及尿动力检查,分析比较两组的临床疗效及安全性。结果:试验组和对照组在治疗前患者OABSS评分、OAB-V8评分以及尿动力检测膀胱初始尿意容量差异均无统计学意义(P＞0.05);试验组和对照组治疗12周后OABSS评分分别为(4.3±1.9)分和(4.8±2.1)分(P＞0.05)、OAB-V8评分分别为(9.3±4.9)分和(11.6±4.7)分(P＜0.05)、尿动力膀胱初始尿意容量分别为(165.5±31.8)mL和(129.0±33.6)mL(P＜0.01);试验组和对照组的治疗有效率分别为86.1%(31/36)和63.8%(23/36)(P＜0.05)。两组患者均未出现严重不良反应。结论:氟哌噻吨美利曲辛治疗感觉敏感性OAB的疗效优于托特罗定,且安全性好,为感觉敏感性OAB的临床治疗提供了新的思路。
- 感觉敏感性 /
- 膀胱过度活动症 /
- 氟哌噻吨美利曲辛 /
- 托特罗定
Abstract: Objective: To explore the efficacy of flupentixol melitracen on female hypersensitivity overactive bladder syndrome(OAB). Method: From July 2019 to December 2019, a total of 72 outpatient patients were chosen and randomly divided into an experimental group and a control group when the following conditions were met: patients complained of persistent micturition desire and urodynamics showed increased bladder sensation without detrusor overactivity. Thirty-six cases in experimental group were treated with flupentixol melitracen(flupentixol 0.5 mg and melitracen 10 mg) orally once daily, while 36 cases in control group were treated with tolterodine 4 mg once daily. Voiding diary, OABSS score, OAB-V8 score, QOL and urodynamics were assessed for each group after 12 weeks. Result: The OABSS, OAB-V8 and the volume of first sense of filling period between two groups showed no difference(P＞0.05) before therapy. Twelve weeks later, OABSS of experimental group and control group were(4.3±1.9) and(4.8±2.1), respectively(P＞0.05). OAB-V8 of the two groups were(9.3±4.9) and(11.6±4.7), respectively(P＜0.05). First sense volume of filling period was(165.5±31.8) ml in the experimental group and(129.0±33.6) ml in the control group(P＜0.01). The effective rate was 86.1%(31/36) in the experimental group and 63.8%(23/36) in the control group(P＜0.05). There was no severely adverse reactions.Conclusion: This study revealed flupentixol melitracen had better efficacy than tolterodine in the treatment of female hypersensitivity OAB. Our findings provide a new approach to the treatment of hypersensitivity OAB and has good security.
- hypersensitivity /
- overactive bladder /
- flupentixol melitracen /
- tolterodine

HTML全文

参考文献(25)

[1]	Stewart WF,Van Rooyen JB,Cundiff GW,et al.Prevalence and burden of overactive bladder in the United States[J].World J Urol,2003,20(6):327-336.
[2]	Irwin DE,Milsom I,Hunskaar S,et al.Population-based survey of urinary incontinence,overactive bladder,and other lower urinary tract symptoms in five countries:results of the EPIC study[J].Eur Urol,2006,50(6):1306-1314.
[3]	Yee CH,Chan CK,Teoh JYC,et al.Survey on prevalence of lower urinary tract symptoms in an Asian population[J].Hong Kong Med J,2019,25(1):13-20.
[4]	Osamu Y,Kazuya H,Masanori N,et al.Defining Overactive Bladder as Hypersensitivity[J].Neurourol Urodyn,2007,26(6 Suppl):904-907.
[5]	Reynolds WS,Mock S,Zhang X,et al.Somatic syndromes and chronic pain in women with overactive bladder[J].Neurourol Urodyn,2017,36(4):1113-1118.
[6]	Liu HT,Jiang YH,Kuo HC.Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy[J].PLoS One,2013,8(10):e76706.
[7]	王东文.膀胱过度活动症诊断治疗指南.见:那彦群.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2014:330-339.
[8]	Flisser AJ,Walmsley K,Blaivas JG.Urodynamic classification of patients with symptoms of overactive bladder[J].J Urol,2003,169(2):529-533.
[9]	诸靖宇,徐智慧,黄邦高,等.辣椒辣素类似物膀胱灌注联合阿米替林治疗感觉敏感型膀胱过度活动症疗效分析[J].浙江医学,2010,32(7):1104-1105.
[10]	金锡御,宋波.临床尿动力学[M].北京:人民卫生出版社,2002:60.
[11]	Blaivas JG,Panagopoulos G,Weiss JP,et al.Two Types of Urgency[J].Neurourol Urodyn,2009,28(3):188-190.
[12]	Herrewegh AGM,Vrijens DMJ,Marcelissen TAT,et al.Bladder sensations in male and female overactive bladder patients compared to healthy volunteers:a sensation-related bladder diary evaluation[J].Scand J Urol,2019,53(4):255-260.
[13]	Basra RK,Cortes E,Khullar V,et al.A comparison study of two lower urinary tract symptoms screening tools in clinical practice:the B-SAQ and OAB-V8 questionnaires[J].J Obstet Gynaecol,2012,32(7):666-671.
[14]	Malde S,Kelly S1,Saad S,et al.Case-finding tools for the diagnosis of OAB in women:A narrative review[J].Neurourol Urodyn,2020,39(1):13-24.
[15]	王涛,张维宇,胡浩,等.女性膀胱过度活动症的尿动力学分型及临床意义[J].中华泌尿外科杂志,2019,40(6):449-455.
[16]	Laet KD,Wachter SD,Wyndaele JJ.Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat:new insights into the working mechanism of antimuscarinics[J].Neurourol Urodyn,2006,25(2):156-161.
[17]	Sakakibara,Tateno F,Yano M,et al.Tolterodine activates the prefrontal cortex during bladder filling in OAB patients:a real-time NIRS-urodynamics study[J].Neurourol Urodyn,2014,33(7):1110-1115.
[18]	Steers WD,Herschorn S,Kreder KJ,et al.Duloxetine compared with placebo for treating women with symptoms of overactive bladder[J].BJU Int,2007,100(2):337-345.
[19]	Abraham N,Goldman HB.An update on the pharmacotherapy for lower urinary tract dysfunction[J].Expert Opin Pharmacother,2015,16(1):79-93.
[20]	Reynolds WS,Dmochowski R,Wein A,et al.Does central sensitization help explain idiopathic overactive bladder?[J].Nat Rev Urol,2016,13(8):481-491.
[21]	Qin L,Qin J,Yang Q,et al.Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome:A systematic review and meta-analysis[J].Medicine(Baltimore),2019,98(2):e14064.
[22]	Redaelli M,Ricatti MJ,Simonetto M,et al.Serotonin and noradrenaline reuptake inhibitors improve micturition control in mice[J].PLoS One,2015,10(3):e0121883.
[23]	Schwen Z1,Matsuta Y,Shen B,et al.Involvement of 5-HT3 receptors in pudendal inhibition of bladder overactivity in cats[J].Am J Physiol Renal Physiol,2013,305(5):F663-671.
[24]	Khaled SM,Elhilali M.Role of 5-HT receptors in treatment of overactive bladder[J].Drugs Today(Barc),2003,39(8):599-607.
[25]	Kummeling MTM,Egberts J,Elzevier HW,et al.Exploratory analysis of the effect of mirabegron on urodynamic sensation parameters and urethral pressure variations[J].Int Urogynecol J,2020 [Epub ahead of print].